With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing ...
WU-KONG28 was an open-label, randomized, confirmatory phase 3 study across 16 countries, using blinded independent central review–assessed PFS as the primary end point. Sunvozertinib improved PFS ...
Pooled evidence from 2 randomized trials and 6 observational cohorts suggests posttransplant gilteritinib maintenance may ...
PARADIGM data suggest azacitidine plus venetoclax improves AML event-free survival vs 7+3 with less toxicity; survival looks ...
A patient's chronological age is no longer a barrier to allogeneic stem cell transplant in MDS/MPN, according to David ...
Paul G. Richardson, MD, explains the distinct potential roles and combinations including iberdomide and mezigdomide in multiple myeloma treatment. Paul G. Richardson, MD, director of Clinical Research ...
Determining the optimal second-line approach in patients with metastatic clear cell renal cell carcinoma (ccRCC) who have progressed either on 1 or 2 lines of therapy and who had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results